# Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

> **NCT04665310** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 46 (actual)

## Conditions studied

- Kidney Disease, End-Stage
- Donor Specific Antibodies
- Acute Rejection of Renal Transplant

## Interventions

- **DRUG:** Envarsus XR

## Key facts

- **NCT ID:** NCT04665310
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665310, "Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04665310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*